Stock Market Reviews

ASND (Ascendis Pharma A/S) News

Get the latest news, insights, and market updates on ASND (Ascendis Pharma A/S). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
  COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigational once-weekly TransCon® CNP (navepegritide) in children with achondroplasia have been published in JAMA Pediatrics, a journal of the American Medical Association. In the publication, titled “Once-Weekly Navepegritide in Children with Achondroplasia: The ApproaCH Randomized Clinic
  Nov 17, 2025 - $ASND
• Liberty All-Star® Growth Fund, Inc. October 2025 Monthly Update
  BOSTON, November 14, 2025--Liberty All-Star® Growth Fund, Inc. October 2025 Monthly Update
  Nov 14, 2025 - $ASND
• A Look at Ascendis Pharma (NasdaqGS:ASND) Valuation Following Q3 Growth and Pipeline Progress
  Ascendis Pharma (NasdaqGS:ASND) shares were on the move following its third-quarter earnings, which featured strong year-over-year revenue growth along with a narrowing net loss. The report also highlighted steady commercial progress for key therapies. See our latest analysis for Ascendis Pharma. Following these upbeat earnings and new clinical milestones, Ascendis Pharma’s share price has gained solid momentum, showing a 49.6% rise year-to-date, while the total shareholder return over the...
  Nov 14, 2025 - $ASND
• European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
  European equities traded in the US as American depositary receipts were tracking lower late Friday m
  Nov 14, 2025 - $ASND
• How the Narrative for Ascendis Pharma Is Evolving Amid New Analyst Optimism and Challenges
  Ascendis Pharma’s consensus analyst price target has recently increased from $245.61 to $258.77 per share. This reflects a renewed sense of optimism as Yorvipath’s uptake accelerates and real-world usage expands. This moderate rise in fair value comes amid positive feedback from endocrinologists and encouraging updates surrounding regulatory and payor developments. Follow along to see how you can stay informed as the outlook for Ascendis Pharma continues to evolve. Analyst Price Targets don't...
  Nov 14, 2025 - $ASND
• Ascendis Pharma AS (ASND) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
  Ascendis Pharma AS (ASND) reports robust financial performance with significant revenue growth and strategic advancements in global markets.
  Nov 13, 2025 - $ASND
• Ascendis (ASND) Q3 2025 Earnings Call Transcript
  Joining me on the call today are Jan Moller Mikkelsen, President and Chief Executive Officer; Scott T. Smith, Executive Vice President and Chief Financial Officer; Sherrie Glass, Chief Business Officer; Jay Donovan Wu, EVP and President, US Markets; and Aimee Shu, EVP and Chief Medical Officer. Before we begin, I'd like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act.
  Nov 13, 2025 - $ASND
• Ascendis Pharma Reports Third Quarter 2025 Financial Results
  – Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® – Q3 2025 operating profit of €11.0 million – TransCon® CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the third quarter ended September 30, 2025, and provided a bus
  Nov 12, 2025 - $ASND
• Apple Upgraded, DraftKings Downgraded: Updated Rankings on Top Blue-Chip Stocks
  During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 165 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Up
  Nov 10, 2025 - $ASND
• The Bull Case For Ascendis Pharma (ASND) Could Change Following New Long-Term Renal Data on TransCon PTH
  Ascendis Pharma recently announced results from a pooled three-year analysis of its Phase 2 and Phase 3 trials showing that adults with hypoparathyroidism treated with TransCon PTH experienced sustained and clinically meaningful improvements in renal function, with most patients achieving independence from conventional therapy and maintaining normal calcium levels. This long-term data, presented at Kidney Week 2025, further supports the safety and efficacy profile of TransCon PTH, which is...
  Nov 9, 2025 - $ASND